![]()
|
|
||||||||
J Biol Chem, Vol. 275, Issue 13, 9106-9109, March 31, 2000
From the § Department of Pharmacology, University of
Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
The Ras oncogene regulates cellular
proliferation, differentiation, transformation, and survival through
multiple downstream signals. Ras signals through its effector
phosphoinositide 3 (PI3) kinase to the Pak protein kinase
(p65pak), but the steps from Ras to Pak remain
to be elucidated. PI3 kinase can stimulate the small G protein, Rac, a
direct activator of Pak, as well as the Akt proto-oncogene, a
serine-threonine protein kinase. We found that activated Akt stimulated
Pak, whereas a dominant negative Akt inhibited Ras activation of Pak in
transfection assays. Akt stimulation of Pak was not inhibited by
dominant negative mutants of either Rac or Cdc42 suggesting that Akt
activated Pak through a GTPase-independent mechanism. We also
developed a novel cell-free system to study Ras activation of Pak. In
this system Ras activated Pak only in the presence of a crude cell
extract but failed to activate Pak when Akt was immunodepleted from the extract. Akt protects cells from apoptosis through phosphorylation of
downstream targets such as the Bcl-2 family member, Bad. We found that
activated Pak decreased apoptosis and increased phosphorylation of Bad,
whereas dominant negative Pak increased apoptosis and decreased
phosphorylation of Bad. These studies define a new oncogene-mediated cell survival signal.
Cell transformation requires modulation of signals from oncogenes
to stimulate anchorage-independent proliferation, rearrange the actin
cytoskeleton, and promote cell survival. This is achieved through the
coordinated regulation of multiple signals. The Ras oncogene, a small G
protein, can promote these three events through downstream targets such
as Raf and phosphoinositide 3 (PI3)1 kinase (1-3). PI3
kinase regulates the actin cytoskeleton through the small G protein,
Rac, and promotes cell survival through the Akt proto-oncogene (also
known as PKB Transfection Assays for Kinase Activity--
Rat-1 cells were
transfected with 1 µg of Pak, 1.5 µg of each test plasmid, and
2.5-4 µg of pUC19 plasmid, as required, to bring the total to 5 µg
of total DNA. The plasmids and immune kinase assays to measure Pak
activity have been described elsewhere (6, 16, 18, 19).
Cell-free Activation of Pak--
H-Ras was purified as a
glutathione S-transferase fusion protein. K-Ras 4B-D12 was
purified from a baculovirus expression system using DE-52
chromatography and a gel filtration column as described (20). Cell
lysates were prepared by washing cells with cold phosphate-buffered
saline followed by lysis with 40 mM HEPES (pH 7.4), 1%
Nonidet P-40, 100 mM NaCl, 1 mM EDTA, 25 mM NaF, 1 mM sodium orthovanadate, 10 µg/ml
leupeptin, 10 µg/ml aprotinin. Samples were then centrifuged at
12000 × g for 20 min at 4 °C, and the supernatants
were collected and frozen until needed. Ras was activated by incubating
2 µg of Ras in 1 mM GTP, 50 mM EDTA for
1 h followed by treatment with 50 mM
MgCl2. Pak was prepared from Rat-1 cells transfected with
Myc-tagged Pak1 and incubated with 9E10 antibody and protein A-agarose
for 2 h at 4 °C. Samples were mixed for 30 min on a rotating
incubator at 4 °C and washed three times with lysis buffer and twice
with 2× phosphorylation buffer (10 mM MgCl2,
40 mM HEPES, pH 7.4). Samples were then incubated with 5 µg of peptide p47phox 324-331 (21) for 5 min
on ice. Kinase assays were initiated by the addition of 10 µCi of
[32P]ATP (3000 Ci/mmol) and 20 µM (final
concentration) ATP following incubation for 20 min at 22 °C. Next,
25 µl of the reaction samples were loaded onto SpinZymeTM
phosphocellulose units (Pierce), centrifuged through the membrane into
collection tubes (for 30 s), washed twice with 500 µl of wash
solution (75 mM phosphoric acid), and filters were counted.
Several proteins are regulated by PI3 kinase including the Akt
protein kinase and the p70 ribosomal protein S6 kinase
(p70S6K). To test whether Akt signals to Pak, we
co-transfected Akt into Rat-1 cells and assayed Pak in an immune kinase
assay using MBP as a substrate. Akt stimulated Pak about 10-fold over
basal levels, whereas activated Pak failed to stimulate Akt (Fig.
1; data not shown for Akt kinase assays).
Pak stimulation was seen following overexpression of two different Akt
constructs, wild-type and membrane-targeted Akt but not K179M, a
kinase-deficient mutant. In most experiments stimulation by Akt was
about half the maximum observed with Rac and about the same as that
observed with PI3 kinase. The p70S6K inhibitor, rapamycin,
had no effect (data not shown). These data suggest that Akt but not
p70S6K is upstream of Pak.
To determine whether Akt was required to mediate the signal from Ras to
Pak we tested K179M, a dominant negative Akt mutant. K179M inhibited
both Ras and PI3 kinase activation of Pak but not Rac activation of Pak
(Fig. 2a). LY294002, a
specific PI3 kinase inhibitor, inhibited both Ras and PI3 kinase
activation of Pak but did not block Akt or Rac activation of Pak (Fig.
2b). These experiments place Akt downstream of Ras and PI3
kinase but upstream of, or perhaps parallel to, Rac. To place Akt
relative to Rac and Cdc42 we tested the effects of the dominant
negative mutants RacN17 and Cdc42N17 on Akt
activation of Pak. Although both dominant negative mutants partially
blocked Ras activation of Pak, neither mutant inhibited Akt activation
of Pak (Fig. 2c). Together these data suggest that Akt is an
essential mediator of Ras activation of Pak but stimulates Pak
independently of Rac and Cdc42.
ACCELERATED PUBLICATION
The Akt Proto-oncogene Links Ras to Pak and Cell Survival
Signals*
§¶,
§,
, and
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
) (4-7). Akt is a serine-threonine kinase that promotes
cell survival by regulating factors such as Bad, caspase-9, forkhead,
and nuclear factor
B (8-12). Another family of effectors downstream
of PI3 kinase are the serine-threonine kinases
p65pak (Pak), which are direct targets of both
Rac and Cdc42 (13-15). In many cells Pak mediates signals directly
from Ras through PI3 kinase to sustain cell transformation, but the
steps from PI3 kinase to Pak remain poorly understood (16-18). Here we
show that Akt is a key intermediate between Ras and Pak. In addition,
activated Pak decreases apoptosis, whereas dominant negative Pak
increases apoptosis. These studies define a new Akt survival signal.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (43K):
[in a new window]
Fig. 1.
Akt activates Pak. Rat-1 cells were
transfected with the indicated plasmids along with a Pak-expressing
plasmid. Pak activity was measured by an immune kinase assay. MBP was
used as the substrate; Pak also autophosphorylates and is seen as a
band at ~65 kDa. The bar graph shows radioactivity
incorporated into MBP quantitated on a phosphoimager and expressed as
-fold activation relative to vector control. Data are the mean ± S.E. of three independent experiments. Western blots at the
bottom show expression of the transfected proteins. PI3
kinase (PI-3K) (p110caax) and Pak were both
Myc-tagged.

View larger version (26K):
[in a new window]
Fig. 2.
Ras activation of Pak is inhibited by a
kinase-inactive, dominant negative Akt. Transfections and immune
kinase assays were performed as described in Fig. 1. Below
each gel lane is the quantitation by phosphoimager analysis.
a, effect of kinase-deficient Akt on Ras, Rac, and PI3
kinase (p110caax) activation of Pak. b, effect
of the PI3 kinase inhibitor LY294002 on Ras, Rac, PI3 kinase, and Akt
activation of Pak. c, effect of dominant negative mutants of
Rac and Cdc42 on Ras and Akt activation of Pak.
To confirm the transfection studies we developed a cell-free system as
an independent assay for Ras activation of Pak. In this system purified
recombinant H-Ras or K-Ras (K-Ras 4B-D12) is incubated with extracts
from cells expressing Myc-tagged Pak, Pak is then immunoisolated, and
its activity is measured using MBP as a substrate (Fig.
3a). Pak was activated with
Ras-GTP, but not Ras-GDP or GTP alone. Hence, only the GTP-activated
Ras activates Pak. We modified the cell-free system by employing a rapid filter binding assay to measure phosphorylation of a specific Pak
substrate, a peptide derived from the p47phox
phosphorylation site (21). With this modified assay, the three key
components, Ras-GTP, Pak (immunoisolated from transfected Rat-1 cells),
and the cell lysate (prepared from untransfected cells), are added
separately, which allowed us to rapidly screen different cells.
Extracts from Rat-1 cells, MCF-7 cells, Schwann cells, pig brain, and
pig spleen all supported substantial levels of Pak activation, but NIH
3T3 cells showed minimal complementation (Fig. 3b; data
shown only for Rat-1 and NIH 3T3 cells). In addition, Ras stimulated
the activity of immunoisolated Pak1, Pak2, and Pak3 from Rat-1 cells
(data not shown). Thus the Ras to Pak signal is common to many cell
types and multiple Pak isoforms. Next, to test whether Akt was required
in the cell-free system, we depleted the Rat-1 extracts with anti-Akt
antibodies (Fig. 3c, inset). Extract incubated
with Akt antibodies was almost devoid of activity, whereas extracts
incubated with either a nonspecific control antibody or with an
antibody against p70S6K still supported robust activation
(Fig. 3c). We obtained similar results when we substituted
Pak purified from a baculovirus expression system for the
immunoisolated Pak in these experiments (data not shown). These
experiments support data from the transfection assays that suggest that
Akt, but not p70S6K, mediates Ras activation of Pak.
|
Akt mediates signals from Ras and PI3 kinase to promote survival in
part by phosphorylating and inactivating apoptotic factors such as Bad
(22, 23). Because Pak is downstream of Akt, we determined whether Pak
affects cell survival signals. We tested PI3
kinase-dependent survival by inducing apoptosis by serum
starvation or serum starvation combined with 20 µM
LY294002. This concentration was chosen because it inhibits Ras
activation of Pak about 80% in transfection assays (18) and produces a
moderate amount of cell death, which allows detection of both increases
and decreases in apoptosis (data not shown). Cells treated under both
conditions displayed changes characteristic of apoptosis, including
cell shrinkage, membrane blebbing, nuclear condensation, and DNA
fragmentation. To test the role of Pak, we utilized G418-selected mass
cultures of Rat-1 cells stably expressing Pak mutants. The cell lines
that we generated express Pak at levels about 2-fold above the
endogenous Pak1. The constructs used in these studies were wild-type
Pak1, Pak1L83,L86 (activated Pak), Pak1R299,
and Pak1L83,L86,R299. The latter two mutants are
kinase-deficient; PakL83,L86,R299 also fails to bind Rac
and Cdc42. Both kinase-deficient mutants inhibit Ras signaling and
transformation in many cell lines and are specific inhibitors of Pak,
and cell lines expressing these mutants are resistant to Ras
transformation (16, 17). In each paradigm, activated Pak1,
PakL83,L86, protected cells by delaying apoptosis, whereas
both PakR299 and PakL83,L86,R299 stimulated
cells to initiate apoptosis earlier than control cells. Wild-type Pak
had no effect (Fig. 4a; data
not shown for serum starvation alone). In another paradigm, a
transiently transfected kinase-deficient Pak mutant increased apoptosis
and reduced protection by transfected Akt (Fig. 4b). The
data in Fig. 4, a and b, suggest that Pak
mediates cell survival signals downstream of PI3 kinase and Akt.
|
One of the downstream targets of Akt associated with cell survival is
Bad, a pro-apoptotic Bcl-2 family protein that is inactivated by
phosphorylation. Pak also phosphorylates Bad in vivo and
in vitro at the key regulatory residues, Serines 112 and
136, which correlates with a cell-protective function (24). We
determined the levels of phosphorylated Bad in the cell lines
expressing Pak using a phosphospecific antibody for Serine 136 of Bad
(Fig. 4c). In parental cells and cells transfected with
kinase-inactive Pak mutants we were unable to detect any phosphorylated
Bad. However, significantly more phosphorylated Bad was observed in
cells expressing both wild-type and the activated
Pak1L83,L86. All of the cell lines expressed comparable
levels of Bad, suggesting that Pak does not alter the levels of Bad
expressed in cells. We found that the levels of Bad expressed in our
cells were too low to reliably measure, so we developed a transfection
assay to test the role of Pak relative to Akt in Bad signaling. This assay measured phosphorylation of transfected Bad. As observed in the
stable cell lines, we found that transfection of
Pak1L83,L86 stimulated Bad phosphorylation (Fig.
4d), whereas the two dominant negative Pak1 mutants did not.
Wild-type Pak also stimulated phosphorylation of Bad but not as
effectively as Pak1L83,L86. Furthermore, the two dominant
negative Pak1 mutants inhibited Ras-, PI3 kinase-, and Akt-stimulated
phosphorylation, whereas dominant negative Akt did not inhibit
Pak-stimulated phosphorylation of Bad (Fig. 4, e and
f). These data suggest that Pak can mediate signals from Akt
to Bad.
| |
DISCUSSION |
|---|
|
|
|---|
We provide four lines of evidence that Akt mediates the signal
from Ras to Pak. First, overexpression of wild-type Akt or an activated
Akt mutant stimulates Pak; second, a kinase-deficient Akt mutant
inhibits Ras activation of Pak; third, extracts depleted of Akt fail to
support Ras activation of Pak in a cell-free system; and fourth, we
placed Pak downstream of Akt in signals to Bad. Together, these data
suggest a Ras
PI3 kinase
Akt
Pak
Bad signal (Fig.
5). This signal promotes cell survival,
because expression of activated Pak delays apoptosis, whereas
expression of two dominant negative mutants of Pak enhances apoptosis.
A total of three apoptosis paradigms that utilize Ras signaling
pathways yielded similar results. Together, these data suggest that Pak
promotes cell survival by inhibiting apoptosis. Bad is one target that
may mediate the cell survival function of Pak, but other potential
survival targets include members of the extracellular signal-regulated
kinase cascade (16, 25, 26).
|
Akt activation of Pak occurs downstream of PI3 kinase, because kinase-deficient Akt blocks both Ras and PI3 kinase activation of Pak. Interestingly, unlike almost all known activators of Pak including Ras and PI3 kinase, neither Rac nor Cdc42 are required for Akt activation of Pak. The simplest model is that Akt phosphorylates Pak to stimulate its activity, because activation of Pak by Akt requires a functional kinase activity. However, Akt is activated by PI3 kinase through direct and indirect mechanisms, and the Akt regulatory kinase, PDK1, can phosphorylate Pak, so the stimulation of Pak by Akt may come about through multiple mechanisms (27).2 Although the Akt pathway is sufficient for activation, our data also suggest, however, that signals from both Akt and Rac/Cdc42 contribute to Ras activation of Pak in vivo. Hence, Pak activation may be analogous to Ras activation of Raf where a small G protein and protein kinases coordinate signals. Although Ras can bind and activate Raf, sustained activation is achieved after Ras recruits Raf to the membrane where it is phosphorylated by several protein kinases including Src and Pak (25).
Recent studies have suggested both pro-apoptotic and anti-apoptotic roles for Pak. In Xenopus oocytes Pak activation is anti-apoptotic (29). However, another member of the Pak family, Pak2, is cleaved and activated by caspase 3. Caspase-activated Pak2 induces a number of morphological features associated with apoptosis including cell shrinkage, externalization of phosphatidylserine, and formation of apoptotic bodies (30, 31). Pak1 is not a substrate for caspases; therefore, depending on the susceptibility to caspase cleavage, different members of the Pak family may either perform pro-apoptotic or anti-apoptotic functions. This is similar to Bcl-2 family members that switch from anti-apoptotic to pro-apoptotic roles following caspase cleavage (32).
In sum, our studies provide evidence for a novel survival signaling
pathway through Pak (Fig. 5). Therefore agents that inhibit Pak, like
those that inhibit Ras processing (28), may both reduce cell
proliferation and shrink tumors by promoting apoptosis.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Gideon Bollag for the baculovirus K-Ras4B-D12 expression system and Morris Birnbaum for the Akt constructs. We also thank Gary Bokoch, Amita Sehgal, Margaret Chou, and members of their respective laboratories for helpful discussions.
| |
FOOTNOTES |
|---|
* This work is supported by National Institutes of Health Grants NS32465 (to R. P.) and GM48241 (to J. F.) and by grants (to J. F.) from the Lucille P. Markey Charitable Trust, the Neurofibromatosis Foundation, and the American Cancer Society.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Contributed equally to this work.
¶ Present address: Dupont Pharmaceuticals Co., Glenolden Lab., Glenolden, PA 19036.
To whom correspondence may be addressed. Tel: 215-898-9736;
Fax: 215-573-2236; E-mail: pittman@pharm.med.upenn.edu.
** To whom correspondence may be addressed. Tel.: 215-898-1912; Fax: 215-573-2236; E-mail: field@pharm.med.upenn.edu.
2 Gary Bokoch, personal communication.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: PI3, phosphoinositide 3; MBP, myelin basic protein; p70S6K, p70 ribosomal protein S6 kinase.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Lowy, D. R., and Willumsen, B. R. (1993) Annu. Rev. Biochem. 62, 851-891[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Egan, S. E., and Weinberg, R. A. (1993) Nature 365, 781-783[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Marshall, M. S. (1995) FASEB J. 9, 1311-1318[Abstract] |
| 4. |
Yao, R.,
and Cooper, G.
(1995)
Science
267,
2003-2006 |
| 5. | Kauffmann-Zeh, A., Rodriguez-Viciana, P., Ulrich, E., Gilbert, C., Coffer, P., Downward, J., and Evan, G. (1997) Nature 385, 544-548[CrossRef][Medline] [Order article via Infotrieve] |
| 6. |
Dudek, H.,
Datta, S. R.,
Franke, T. F.,
Birnbaum, M. J.,
Yao, R.,
Cooper, G. M.,
Segal, R. A.,
Kaplan, D. R.,
and Greenberg, M. E.
(1997)
Science
275,
661-665 |
| 7. | Franke, T. F., Kaplan, D. R., and Cantley, L. C. (1997) Cell 88, 435-437[CrossRef][Medline] [Order article via Infotrieve] |
| 8. |
Cardone, M. H.,
Roy, N.,
Stennicke, H. R.,
Salvesen, G. S.,
Franke, T. F.,
Stanbridge, E.,
Frisch, S.,
and Reed, J. C.
(1998)
Science
282,
1318-1321 |
| 9. | Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., and Greenberg, M. E. (1999) Cell 96, 857-868[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Belham, C., Wu, S., and Avruch, J. (1999) Curr. Biol. 9, 93-96[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Ozes, O. N., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., and Donner, D. B. (1999) Nature 401, 82-85[CrossRef][Medline] [Order article via Infotrieve] |
| 12. | Romashkova, J. A., and Makarov, S. S. (1999) Nature 401, 86-90[CrossRef][Medline] [Order article via Infotrieve] |
| 13. | Manser, E., Leung, T., Salihuddin, H., Zhao, Z.-S., and Lim, L. (1994) Nature 367, 40-46[CrossRef][Medline] [Order article via Infotrieve] |
| 14. | Sells, M. A., and Chernoff, J. (1997) Trends Cell Biol. 7, 162-167 |
| 15. | Lim, L., Manser, E., Leung, T., and Hall, C. (1996) Eur. J. Biochem. 242, 171-185[Medline] [Order article via Infotrieve] |
| 16. | Tang, Y., Chen, Z., Ambrose, D., Liu, J., Gibbs, J. B., Chernoff, J., and Field, J. (1997) Mol. Cell. Biol. 17, 4454-4464[Abstract] |
| 17. |
Tang, Y.,
Marwaha, S.,
Rutkowski, J. L.,
Tennekoon, G. I.,
Phillips, P. C.,
and Field, J.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
5139-5144 |
| 18. |
Tang, Y., Yu, J.,
and Field, J.
(1999)
Mol. Cell. Biol.
19,
1881-1891 |
| 19. |
Zhou, H.,
Summers, S. S.,
Birnbaum, M. J.,
and Pittman, R. N.
(1998)
J. Biol. Chem.
273,
16568-16575 |
| 20. |
Lowe, P. N.,
Page, M. J.,
Bradley, S.,
Rhodes, S.,
Sydenham, M.,
Paterson, H.,
and Skinner, R. H.
(1991)
J. Biol. Chem.
266,
1672-1678 |
| 21. |
Knaus, U.,
Morris, S.,
Dong, H.-J.,
Chernoff, J.,
and Bokoch, G.
(1995)
Science
269,
221-223 |
| 22. | Datta, S. R., Dudek, H., Tao, X., Master, S., Fu, H., Gotoh, Y., and Greenberg, M. E. (1997) Cell 91, 231-341[CrossRef][Medline] [Order article via Infotrieve] |
| 23. |
del Peso, L.,
Gonzàlez-García, M.,
Page, C.,
Herrera, R.,
and Nuñez, G.
(1997)
Science
278,
687-689 |
| 24. |
Schürmann, A.,
Mooney, A. F.,
Sanders, L. C.,
Sells, M. A.,
Wang, H.-G.,
Reed, J. C.,
and Bokoch, G. M.
(2000)
Mol. Cell. Biol.
20,
453-461 |
| 25. | King, A. J., Sun, H., Diaz, B., Barnard, D., Miao, W., Bagrodia, S., and Marshall, M. S. (1998) Nature 396, 180-183[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Frost, J. A., Steen, H., Shapiro, P., Lewis, T., Ahn, N., Shaw, P. E., and Cobb, M. H. (1997) EMBO J. 16, 6426-6438[CrossRef][Medline] [Order article via Infotrieve] |
| 27. |
Stokoe, D.,
Stephens, L. R.,
Copeland, T.,
Gaffney, P. R.,
Reese, C. B.,
Painter, G. F.,
Holmes, A. B.,
McCormick, F.,
and Hawkins, P. T.
(1997)
Science
277,
567-570 |
| 28. | Barrington, R., Subler, M., Rands, E., Omer, C., Miller, P., Hundley, J., Koester, S., Troyer, D., Bearss, D., Conner, M., Gibbs, J., Hamilton, K., Koblan, K., Mosser, S., O'Neill, T., Schaber, M., Senderak, E., Windle, J., Oliff, A., and Kohl, N. (1998) Mol. Cell. Biol. 85-92 |
| 29. | Faure, S., Vigneron, S., Doree, M., and Morin, N. (1997) EMBO J. 16, 5550-5561[CrossRef][Medline] [Order article via Infotrieve] |
| 30. |
Rudel, T.,
and Bokoch, G. M.
(1997)
Science
276,
1571-1574 |
| 31. |
Lee, N.,
MacDonald, C.,
Halenbeck, R.,
Roulston, A.,
Shi, T.,
and Williams, L.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
13642-13647 |
| 32. |
Cheng, E. H.,
Kirsch, D. G.,
Clem, R. J.,
Ravi, R.,
Kastan, M. B.,
Bedi, A.,
Ueno, K.,
and Hardwick, J. M.
(1997)
Science
278,
1966-1968 |
This article has been cited by other articles:
![]() |
Y. Liu, H. Xiao, Y. Tian, T. Nekrasova, X. Hao, H. J. Lee, N. Suh, C. S. Yang, and A. Minden The Pak4 Protein Kinase Plays a Key Role in Cell Survival and Tumorigenesis in Athymic Mice Mol. Cancer Res., July 1, 2008; 6(7): 1215 - 1224. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Mayhew, E. D. Jeffery, N. E. Sherman, K. Nelson, J. M. Polefrone, S. J. Pratt, J. Shabanowitz, J. T. Parsons, J. W. Fox, D. F. Hunt, et al. Identification of phosphorylation sites in betaPIX and PAK1 J. Cell Sci., November 15, 2007; 120(22): 3911 - 3918. [Full Text] [PDF] |
||||
![]() |
L. Rider, A. Shatrova, E. P. Feener, L. Webb, and M. Diakonova JAK2 Tyrosine Kinase Phosphorylates PAK1 and Regulates PAK1 Activity and Functions J. Biol. Chem., October 19, 2007; 282(42): 30985 - 30996. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Kissil, M. J. Walmsley, L. Hanlon, K. M. Haigis, C. F. Bender Kim, A. Sweet-Cordero, M. S. Eckman, D. A. Tuveson, A. J. Capobianco, V. L.J. Tybulewicz, et al. Requirement for Rac1 in a K-ras Induced Lung Cancer in the Mouse Cancer Res., September 1, 2007; 67(17): 8089 - 8094. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.-L. Zhou, D. F. Tucker, S. S. Bae, K. Bhatheja, M. J. Birnbaum, and J. Field Opposing Roles for Akt1 and Akt2 in Rac/Pak Signaling and Cell Migration J. Biol. Chem., November 24, 2006; 281(47): 36443 - 36453. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Wang, I. Shin, F. Y. Wu, D. B. Friedman, and C. L. Arteaga HER2/Neu (ErbB2) Signaling to Rac1-Pak1 Is Temporally and Spatially Modulated by Transforming Growth Factor {beta} Cancer Res., October 1, 2006; 66(19): 9591 - 9600. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. R. Sastry, Y. Karpova, and G. Kulik Epidermal Growth Factor Protects Prostate Cancer Cells from Apoptosis by Inducing BAD Phosphorylation via Redundant Signaling Pathways J. Biol. Chem., September 15, 2006; 281(37): 27367 - 27377. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Schade, J. J. Powers, M. W. Wlodarski, and J. P. Maciejewski Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis Blood, June 15, 2006; 107(12): 4834 - 4840. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Starlets, Y. Gore, I. Binsky, M. Haran, N. Harpaz, L. Shvidel, S. Becker-Herman, A. Berrebi, and I. Shachar Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival Blood, June 15, 2006; 107(12): 4807 - 4816. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. H. Fryer, C. Wang, S. Vedantam, G.-L. Zhou, S. Jin, L. Fletcher, M. C. Simon, and J. Field cGMP-dependent Protein Kinase Phosphorylates p21-activated Kinase (Pak) 1, Inhibiting Pak/Nck Binding and Stimulating Pak/Vasodilator-stimulated Phosphoprotein Association J. Biol. Chem., April 28, 2006; 281(17): 11487 - 11495. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Belmonte, M. F. Santos, A. H. Kihara, C. Y. I. Yan, and D. E. Hamassaki Light-Induced Photoreceptor Degeneration in the Mouse Involves Activation of the Small GTPase Rac1. Invest. Ophthalmol. Vis. Sci., March 1, 2006; 47(3): 1193 - 1200. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Howells, E. A. Hudson, and M. M. Manson Inhibition of Phosphatidylinositol 3-Kinase/Protein Kinase B Signaling Is Not Sufficient to Account for Indole-3-Carbinol-Induced Apoptosis in Some Breast and Prostate Tumor Cells Clin. Cancer Res., December 1, 2005; 11(23): 8521 - 8527. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Wilkes, H. Mitchell, S. G. Penheiter, J. J. Dore, K. Suzuki, M. Edens, D. K. Sharma, R. E. Pagano, and E. B. Leof Transforming Growth Factor-{beta} Activation of Phosphatidylinositol 3-Kinase Is Independent of Smad2 and Smad3 and Regulates Fibroblast Responses via p21-Activated Kinase-2 Cancer Res., November 15, 2005; 65(22): 10431 - 10440. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Beeser, Z. M. Jaffer, C. Hofmann, and J. Chernoff Role of Group A p21-activated Kinases in Activation of Extracellular-regulated Kinase by Growth Factors J. Biol. Chem., November 4, 2005; 280(44): 36609 - 36615. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Cammarano, T. Nekrasova, B. Noel, and A. Minden Pak4 Induces Premature Senescence via a Pathway Requiring p16INK4/p19ARF and Mitogen-Activated Protein Kinase Signaling Mol. Cell. Biol., November 1, 2005; 25(21): 9532 - 9542. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Ray Protection of Epithelial Cells by Keratincoyte Growth Factor Signaling Proceedings of the ATS, October 1, 2005; 2(3): 221 - 225. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. K. Misra, T. Sharma, and S. V. Pizzo Ligation of Cell Surface-Associated Glucose-Regulated Protein 78 by Receptor-Recognized Forms of {alpha}2-Macroglobulin: Activation of p21-Activated Protein Kinase-2-Dependent Signaling in Murine Peritoneal Macrophages J. Immunol., August 15, 2005; 175(4): 2525 - 2533. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Jin, Y. Zhuo, W. Guo, and J. Field p21-activated Kinase 1 (Pak1)-dependent Phosphorylation of Raf-1 Regulates Its Mitochondrial Localization, Phosphorylation of BAD, and Bcl-2 Association J. Biol. Chem., July 1, 2005; 280(26): 24698 - 24705. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-q. Yuan, D. Kim, S. Kaneko, M. Sussman, G. M. Bokoch, G. D. Kruh, S. V. Nicosia, J. R. Testa, and J. Q. Cheng ArgBP2{gamma} Interacts with Akt and p21-activated Kinase-1 and Promotes Cell Survival J. Biol. Chem., June 3, 2005; 280(22): 21483 - 21490. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Koeppel, C. C. McCarthy, E. Moertl, and R. Jakobi Identification and Characterization of PS-GAP as a Novel Regulator of Caspase-activated PAK-2 J. Biol. Chem., December 17, 2004; 279(51): 53653 - 53664. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Pulkkinen, G. H. Renkema, F. Kirchhoff, and K. Saksela Nef Associates with p21-Activated Kinase 2 in a p21-GTPase-Dependent Dynamic Activation Complex within Lipid Rafts J. Virol., December 1, 2004; 78(23): 12773 - 12780. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. S. Adams and D. Teegarden 1,25-Dihydroxycholecalciferol Inhibits Apoptosis in C3H10T1/2 Murine Fibroblast Cells Through Activation of Nuclear Factor {kappa}B J. Nutr., November 1, 2004; 134(11): 2948 - 2952. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Hofmann, M. Shepelev, and J. Chernoff The genetics of Pak J. Cell Sci., September 1, 2004; 117(19): 4343 - 4354. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Seo, C.-H. Cho, Y.-I. Lee, E.-Y. Shin, D. Park, C.-D. Bae, J. W. Lee, E.-S. Lee, and Y.-S. Juhnn Cdc42-dependent Mediation of UV-induced p38 Activation by G Protein {beta}{gamma} Subunits J. Biol. Chem., April 23, 2004; 279(17): 17366 - 17375. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Sathe, N. Sizemore, X. Li, K. Vithalani, M. Commane, S. M. Swiatkowski, and G. R. Stark Mutant human cells with constitutive activation of NF-{kappa}B PNAS, January 6, 2004; 101(1): 192 - 197. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Dadke, B. H. Fryer, E. A. Golemis, and J. Field Activation of p21-Activated Kinase 1-Nuclear Factor {kappa}B Signaling by Kaposi's Sarcoma-Associated Herpes Virus G Protein-Coupled Receptor during Cellular Transformation Cancer Res., December 15, 2003; 63(24): 8837 - 8847. [Abstract] [Full Text] [PDF] |
||||